Cardiff Oncology shares plunge after Q2 earnings miss
Stacey A. Walker, Senior Vice President of Human Resources at Fortive Corp (NYSE:FTV), recently sold a significant portion of her holdings in the company. According to a Form 4 filing with the Securities and Exchange Commission, Walker sold 5,688 shares of common stock on February 26, 2025, at an average price of $80.52 per share. The total value of this transaction amounted to $457,997. The sale comes as Fortive, currently valued at $27.08 billion, trades near $79.54, showing relatively low price volatility according to InvestingPro analysis.
In addition to the sale, Walker also had two separate transactions related to the withholding of shares for tax purposes following the vesting of performance stock units. These transactions, conducted on February 26 and 27, involved 861 and 905 shares, respectively, with prices ranging from $79.60 to $79.91. The total value of these transactions was $140,840.
Following these transactions, Walker retains ownership of 45,375 shares of Fortive’s common stock.
In other recent news, Fortive Corporation reported its fourth-quarter earnings, revealing a revenue of $1.62 billion, which slightly missed the consensus estimate of $1.63 billion. Despite this, the company exceeded expectations with an adjusted earnings per share (EPS) of $1.17, compared to the anticipated $1.12. For 2025, Fortive forecasts revenue between $6.23 billion and $6.35 billion, which is below Wall Street’s projection of $6.47 billion. The company also provided guidance for an adjusted EPS of $4.00 to $4.12, compared to the consensus estimate of $4.12.
In terms of analyst activity, RBC Capital Markets raised its price target for Fortive from $77 to $85, maintaining a Sector Perform rating, while Raymond (NSE:RYMD) James increased its target from $85 to $90, keeping an Outperform rating. Both firms highlighted Fortive’s strategic direction, particularly the upcoming spin-off of its Precision Technologies segment, which is now expected to occur earlier in the third quarter of 2025. Additionally, Fortive expanded its Board of Directors by appointing Gregory J. Moore, M.D., Ph.D., a recognized leader in AI and healthcare, to support its strategic growth initiatives.
Dr. Moore’s expertise is anticipated to enhance Fortive’s innovation and governance capabilities. The company continues to focus on its strategic execution, with strong order growth reported across all segments, including double-digit growth in its Precision Technologies unit for two consecutive quarters.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.